Details of ADC Therapeutics' oral presentation at AACR are as follows: Title: Preclinical investigation of ADCT-242, a novel exatecan-based antibody drug conjugate targeting Claudin-6, as single ...

All titles, abstracts, photos and YouTube presentations will need your research mentor’s approval prior to submitting your abstract. The abstract will be open to public viewing. Submit your abstract ...

Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases -- SCS Microinjector® Provides ...

Virtual presentations will be judged. Posters will not be judged. Virtual presentation abstracts must be submitted by April 1 at 11:59pm to be included on the Conference site. Poster abstracts can be ...

Presenters must provide the name, institution and email of the non-CWRU mentor (and PI if different) with whom they worked. The project mentor (or PI if different) must approve the research ...

Please note that if your abstract is accepted for an oral presentation, you must also submit a paper which will be included in the conference proceedings. We strongly encourage authors to submit an ...

Abstract Highlights ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and ...

ALPHARETTA, Ga., March 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company ...

today announced the acceptance of seventeen abstracts for presentation at the AACR Annual Meeting, in Chicago, IL (April 25-30, 2025). These presentations will highlight Champions' cutting-edge ...

(“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ®), announced today that six ...